002603 以岭藥業
按盤價 
17.260 +0.140 (+0.818%)
17.260 +0.140 (+0.818%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 6,365,441 | -25.76% | 10,318,313 | 12,532,841 | 10,116,794 | 8,782,480 | |
| 減：營業總成本 | 5,723,859 | -12.97% | 8,719,196 | 9,666,882 | 8,559,711 | 7,342,875 | |
| 其中:營業成本 | 2,966,690 | -11.26% | 4,407,809 | 4,540,572 | 3,680,995 | 3,118,413 | |
| 財務費用 | 25,657 | 171.42% | 26,368 | 19,920 | 17,319 | (1,837) | |
| 資產減值損失 | (4,678) | -70.61% | (35,358) | (108,432) | (28,630) | (58,154) | |
| 公允價值變動收益 | 38,863 | -12.52% | 39,354 | 18,734 | 1,853 | 5,229 | |
| 投資收益 | 501 | -228.64% | 25,950 | (7,229) | (23,748) | 24,372 | |
| 其中：對聯營企業和合營企業的投資收益 | (8) | -17.25% | (15) | (3) | -- | -- | |
| 營業利潤 | 703,134 | -66.97% | 1,779,828 | 2,829,555 | 1,569,071 | 1,438,036 | |
| 利潤總額 | 672,108 | -68.09% | 1,684,211 | 2,780,643 | 1,553,718 | 1,422,472 | |
| 減：所得稅費用 | 123,022 | -65.07% | 339,909 | 422,870 | 212,086 | 207,541 | |
| 淨利潤 | 549,087 | -68.69% | 1,344,303 | 2,357,773 | 1,341,632 | 1,214,931 | |
| 減：非控股權益 | (5,690) | 19.85% | (8,077) | (4,983) | (2,224) | (3,807) | |
| 股東淨利潤 | 554,777 | -68.46% | 1,352,379 | 2,362,756 | 1,343,856 | 1,218,738 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.332 | -68.45% | 0.810 | 1.414 | 0.804 | 0.730 | |
| 每股派息 (元) * | -- | -- | 0.300 | 0.500 | 0.300 | 1.000 | |
| 每股淨資產 (元) * | 6.886 | -2.97% | 6.853 | 6.543 | 5.428 | 7.410 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 19/11/2024 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
